4.7 Editorial Material

Biological activities of drug inactive ingredients

Journal

BRIEFINGS IN BIOINFORMATICS
Volume 23, Issue 5, Pages -

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/bib/bbac160

Keywords

drug inactive ingredient; biological activity; drug formulation; database; artificial intelligence

Funding

  1. Natural Science Foundation of Zhejiang Province [LR21-H300001]
  2. National Natural Science Foundation of China [81872798, U1909208]
  3. Leading Talent of the 'Ten Thousand Plan' -National High-Level Talents Special Support Plan of China
  4. 'Double Top-Class' University Project [181201*194232101]
  5. Key R&D Program of Zhejiang Province [2020C03010]
  6. Fundamental Research Fund for Central Universities [2018QNA7023]
  7. Westlake Laboratory (Westlake Laboratory of Life Sciences and Biomedicine
  8. Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare
  9. Alibaba Cloud
  10. Information Technology Center of Zhejiang University

Ask authors/readers for more resources

This study conducted a comprehensive assessment and analysis on the biological activities of DIGs in drug formulations, providing the first comprehensive activities for both DIGs and DFMs to the pharmaceutical community. The biological targets of each DIG and formulation were fully referenced to available databases, and popular artificial intelligence techniques were used to evaluate the predictive potential of DIGs' activity data. The findings of this work are expected to have significant implications for the future practice of drug discovery and precision medicine.
In a drug formulation (DFM), the major components by mass are not Active Pharmaceutical Ingredient (API) but rather Drug Inactive Ingredients (DIGs). DIGs can reach much higher concentrations than that achieved by API, which raises great concerns about their clinical toxicities. Therefore, the biological activities of DIG on physiologically relevant target are widely demanded by both clinical investigation and pharmaceutical industry. However, such activity data are not available in any existing pharmaceutical knowledge base, and their potentials in predicting the DIG-target interaction have not been evaluated yet. In this study, the comprehensive assessment and analysis on the biological activities of DIGs were therefore conducted. First, the largest number of DIGs and DFMs were systematically curated and confirmed based on all drugs approved by US Food and Drug Administration. Second, comprehensive activities for both DIGs and DFMs were provided for the first time to pharmaceutical community. Third, the biological targets of each DIG and formulation were fully referenced to available databases that described their pharmaceutical/biological characteristics. Finally, a variety of popular artificial intelligence techniques were used to assess the predictive potential of DIGs' activity data, which was the first evaluation on the possibility to predict DIG's activity. As the activities of DIGs are critical for current pharmaceutical studies, this work is expected to have significant implications for the future practice of drug discovery and precision medicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available